Full Text Journal Articles by
Author Michael H Barnett

Advertisement

Find full text journal articles






Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules.

Benjamin P Trewin, Stephen Adelstein, Judith M Spies, Heidi N Beadnall, Joshua Barton, Nicholas Ho, Kerri J Gallagher, Michael H Barnett,

BACKGROUND:B-cell depleting treatments are widely used to modify the course of neuromyelitis optica spectrum disorder (NMOSD). Despite recent successful Phase 3 trials of several novel NMOSD therapies, limited availability and high cost constrains their clinical use, and rituximab (RTX) remains a core treatment in many centres. Since 2013, the Royal ... Read more >>

Mult Scler Relat Disord (Multiple sclerosis and related disorders)
[2020, 43:102175]

Cited: 0 times

View full text PDF listing >>



Alemtuzumab: Rare serious adverse events of a high-efficacy drug.

Hans-Peter Hartung, Jan Mares, Michael H Barnett,

Mult. Scler. (Multiple sclerosis (Houndmills, Basingstoke, England))
[2020, :1352458520913277]

Cited: 0 times

View full text PDF listing >>



Advertisement

Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis.

Yuyi You, Michael H Barnett, Con Yiannikas, John Parratt, Jim Matthews, Stuart L Graham, Alexander Klistorner,

OBJECTIVE:To examine the effect of chronic demyelination in the optic nerve of patients with MS on progressive loss of retinal ganglion cell (RGC) axons. METHODS:Progressive retinal nerve fiber layer (RNFL) loss, as measured by optical coherence tomography, was longitudinally examined in 51 patients with MS with a history of unilateral ... Read more >>

Neurol Neuroimmunol Neuroinflamm (Neurology(R) neuroimmunology & neuroinflammation)
[2020, 7(3):]

Cited: 0 times

View full text PDF listing >>



MRI biomarkers of disease progression in multiple sclerosis: old dog, new tricks?

Yael Barnett, Justin Y Garber, Michael H Barnett,

Quant Imaging Med Surg (Quantitative imaging in medicine and surgery)
[2020, 10(2):527-532]

Cited: 0 times

View full text PDF listing >>



Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

F Schweitzer, S Laurent, G R Fink, Michael H Barnett, H P Hartung, C Warnke,

Modern disease-modifying therapies (DMTs) in multiple sclerosis (MS) have variable modes of action and selectively suppress or modulate the immune system. In this review, we summarize the predicted and intended as well as unwanted adverse effects on leukocytes in peripheral blood as a result of treatment with DMTs for MS. ... Read more >>

J. Neurol. (Journal of Neurology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The clinical profile of NMOSD in Australia and New Zealand.

Wajih Bukhari, Laura Clarke, Cullen O'Gorman, Elham Khalilidehkordi, Simon Arnett, Kerri M Prain, Mark Woodhall, Roger Silvestrini, Christine S Bundell, Sudarshini Ramanathan, David Abernethy, Sandeep Bhuta, Stefan Blum, Mike Boggild, Karyn Boundy, Bruce J Brew, Wallace Brownlee, Helmut Butzkueven, William M Carroll, Celia Chen, Alan Coulthard, Russell C Dale, Chandi Das, Keith Dear, Marzena J Fabis-Pedrini, David Fulcher, David Gillis, Simon Hawke, Robert Heard, Andrew P D Henderson, Saman Heshmat, Suzanne Hodgkinson, Sofia Jimenez-Sanchez, Trevor J Kilpatrick, John King, Chris Kneebone, Andrew J Kornberg, Jeannette Lechner-Scott, Ming-Wei Lin, Christopher Lynch, Richard A L Macdonnell, Deborah F Mason, Pamela A McCombe, Jennifer Pereira, John D Pollard, Stephen W Reddel, Cameron Shaw, Judith Spies, James Stankovich, Ian Sutton, Steve Vucic, Michael Walsh, Richard C Wong, Eppie M Yiu, Michael H Barnett, Allan G Kermode, Mark P Marriott, John Parratt, Mark Slee, Bruce V Taylor, Ernest Willoughby, Robert J Wilson, Fabienne Brilot, Angela Vincent, Patrick Waters, Simon A Broadley,

Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and New Zealand populations with the aim of characterising the clinical features and establishing the value of recently revised diagnostic criteria. ... Read more >>

J. Neurol. (Journal of neurology)
[2020, 267(5):1431-1443]

Cited: 0 times

View full text PDF listing >>



Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry.

Fiona Tea, Deepti Pilli, Sudarshini Ramanathan, Joseph A Lopez, Vera Merheb, Fiona X Z Lee, Alicia Zou, Ganesha Liyanage, Chelsea B Bassett, Selina Thomsen, Stephen W Reddel, Michael H Barnett, David A Brown, Russell C Dale, Fabienne Brilot, ,

Human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have become a useful clinical biomarker for the diagnosis of a spectrum of inflammatory demyelinating disorders. Live cell-based assays that detect MOG Ab against conformational MOG are currently the gold standard. Flow cytometry, in which serum binding to MOG-expressing cells and control ... Read more >>

Front Immunol (Frontiers in immunology)
[2020, 11:119]

Cited: 0 times

View full text PDF listing >>



Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.

Mahtab Ghadiri, Ayman Rezk, Rui Li, Ashley Evans, Paul S Giacomini, Michael H Barnett, Jack Antel, Amit Bar-Or,

Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lacking. Here, we performed extensive functional immunophenotyping using multiparametric flow cytometry to examine peripheral immune changes under FTY treatment and explore biomarkers of FTY treatment response. From among 135 RRMS patients who initiated FTY in a 2-year multicentre ... Read more >>

Sci Rep (Scientific reports)
[2020, 10(1):356]

Cited: 0 times

View full text PDF listing >>



Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment.

Saeideh Ebrahimkhani, Heidi N Beadnall, Chenyu Wang, Catherine M Suter, Michael H Barnett, Michael E Buckland, Fatemeh Vafaee,

We and others have previously demonstrated the potential for circulating exosome microRNAs to aid in disease diagnosis. In this study, we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy. We studied patients with relapsing-remitting multiple sclerosis ... Read more >>

Mol. Neurobiol. (Molecular neurobiology)
[2020, 57(2):1245-1258]

Cited: 0 times

View full text PDF listing >>



AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD.

Kerri Prain, Mark Woodhall, Angela Vincent, Sudarshini Ramanathan, Michael H Barnett, Christine S Bundell, John D E Parratt, Roger A Silvestrini, Wajih Bukhari, , Fabienne Brilot, Patrick Waters, Simon A Broadley,

We have compared five different assays for antibodies to aquaporin-4 in 181 cases of suspected Neuromyelitis optica spectrum disorders (NMOSD) and 253 controls to assess their relative utility. As part of a clinically-based survey of NMOSD in Australia and New Zealand, cases of suspected NMOSD were referred from 23 centers. ... Read more >>

Front Neurol (Frontiers in Neurology)
[2019, 10:1028]

Cited: 0 times

View full text PDF listing >>



Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.

Fiona Tea, Joseph A Lopez, Sudarshini Ramanathan, Vera Merheb, Fiona X Z Lee, Alicia Zou, Deepti Pilli, Ellis Patrick, Anneke van der Walt, Mastura Monif, Esther M Tantsis, Eppie M Yiu, Steve Vucic, Andrew P D Henderson, Anthony Fok, Clare L Fraser, Jeanette Lechner-Scott, Stephen W Reddel, Simon Broadley, Michael H Barnett, David A Brown, Jan D Lunemann, Russell C Dale, Fabienne Brilot, ,

Over recent years, human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have been associated with monophasic and relapsing central nervous system demyelination involving the optic nerves, spinal cord, and brain. While the clinical relevance of MOG Ab detection is becoming increasingly clear as therapeutic and prognostic differences from multiple sclerosis ... Read more >>

Acta Neuropathol Commun (Acta neuropathologica communications)
[2019, 7(1):145]

Cited: 1 time

View full text PDF listing >>



The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis.

Lai Yin Law, D Sean Riminton, MaiAnh Nguyen, Michael H Barnett, Stephen W Reddel, Todd A Hardy,

The presentation of a patient with brainstem symptoms and signs invokes a number of common and less common differential diagnoses, and accurate diagnosis can be challenging. We review the major immune-mediated and inflammatory syndromes that can affect the brainstem including multiple sclerosis, neuromyelitis optica spectrum disorder, neuro-Behçet disease, chronic lymphocytic ... Read more >>

Neurology (Neurology)
[2019, 93(9):390-405]

Cited: 0 times

View full text PDF listing >>



Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Michael G Dwyer, Niels Bergsland, Deepa P Ramasamy, Bianca Weinstock-Guttman, Michael H Barnett, Chenyu Wang, Davorka Tomic, Diego Silva, Robert Zivadinov,

BACKGROUND AND PURPOSE:Quantitative neuroimaging is an important part of multiple sclerosis research and clinical trials, and measures of lesion volume (LV) and brain atrophy are key clinical trial endpoints. However, translation of these endpoints to heterogeneous historical datasets and nonstandardized clinical routine imaging has been difficult. The NeuroSTREAM technique was ... Read more >>

J Neuroimaging (Journal of neuroimaging : official journal of the American Society of Neuroimaging)
[2019, 29(5):615-623]

Cited: 0 times

View full text PDF listing >>



The evaluation of an online mindfulness program for people with multiple sclerosis: study protocol.

Amy-Lee Sesel, Louise Sharpe, Heidi N Beadnall, Michael H Barnett, Marianna Szabo, Sharon L Naismith,

BACKGROUND:Multiple sclerosis (MS) is a neurological disease of the central nervous system and is associated with many psychosocial symptoms that are difficult to manage including low mood, anxiety, fatigue and pain, as well as low health-related quality of life. Internet-based psychosocial interventions that use mindfulness-based approaches are gathering much attention ... Read more >>

BMC Neurol (BMC neurology)
[2019, 19(1):129]

Cited: 0 times

View full text PDF listing >>



Computerized Cognitive Training in Multiple Sclerosis: A Systematic Review and Meta-analysis.

Amit Lampit, Josephine Heine, Carsten Finke, Michael H Barnett, Michael Valenzuela, Anna Wolf, Isabella H K Leung, Nicole T M Hill,

Background. Cognitive impairments are common in people with multiple sclerosis (MS). Systematic reviews reported promising evidence for various cognitive interventions in this population. Computerized cognitive training (CCT) has strong evidence for safety and efficacy in several populations, but its effects in MS have yet to be specified. Objective. We aimed ... Read more >>

Neurorehabil Neural Repair (Neurorehabilitation and neural repair)
[2019, 33(9):695-706]

Cited: 0 times

View full text PDF listing >>



Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis.

Matthew Silsby, Pedro Sánchez, Judith M Spies, Jane Frith, Joshua Barton, Heidi N Beadnall, Michael H Barnett, Stephen W Reddel, Todd A Hardy,

BACKGROUND:Tumefactive demyelinating lesions occur as part of the spectrum of multiple sclerosis (MS), but can be difficult to distinguish from other large cerebral lesions such as neoplasm or abscess. OBJECTIVES:To estimate the cost associated with diagnostic investigation of patients with tumefactive demyelination (TD), including associated morbidity, and compare this to ... Read more >>

Mult Scler Relat Disord (Multiple sclerosis and related disorders)
[2019, 35:104-107]

Cited: 0 times

View full text PDF listing >>



Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS.

Chenyu Wang, Michael H Barnett, Con Yiannikas, Joshua Barton, John Parratt, Yuyi You, Stuart L Graham, Alexander Klistorner,

OBJECTIVE:To evaluate the combined effect of lesion activity and pathologic processes occurring in both chronically demyelinated lesions and normal-appearing white matter (NAWM) on brain atrophy in MS. METHODS:Pre- and post-gadolinium T1, fluid attenuation inversion recovery, and diffusion tensor imaging images were acquired from 50 consecutive patients with relapsing-remitting MS (all, ... Read more >>

Neurol Neuroimmunol Neuroinflamm (Neurology(R) neuroimmunology & neuroinflammation)
[2019, 6(5):]

Cited: 0 times

View full text PDF listing >>



Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.

Hans-Peter Hartung, Jonas Graf, Orhan Aktas, Jan Mares, Michael H Barnett,

PURPOSE OF REVIEW:The purpose of this review is to describe the new 2017 revisions of the McDonald diagnostic criteria for multiple sclerosis and review first experiences in their application to different patient populations. RECENT FINDINGS:The 2017 revisions agreed on by an international expert panel, as the precursors, define criteria needed ... Read more >>

Curr. Opin. Neurol. (Current opinion in neurology)
[2019, 32(3):327-337]

Cited: 0 times

View full text PDF listing >>



Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.

Finja Schweitzer, Sarah Laurent, Gereon R Fink, Michael H Barnett, Stephen Reddel, Hans-Peter Hartung, Clemens Warnke,

PURPOSE OF REVIEW:A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected ... Read more >>

Curr. Opin. Neurol. (Current opinion in neurology)
[2019, 32(3):305-312]

Cited: 2 times

View full text PDF listing >>



The electrophysiological assessment of visual function in Multiple Sclerosis.

Joshua L Barton, Justin Y Garber, Alexander Klistorner, Michael H Barnett,

The assessment of vision is integral to the diagnosis and monitoring of patients with multiple sclerosis (MS). Visual electrophysiology, previously a critical investigation in patients with suspected MS, has in large part been supplanted by magnetic resonance imaging in clinical routine. However, the development of multi-focal visual evoked potentials and ... Read more >>

Clin Neurophysiol Pract (Clinical neurophysiology practice)
[2019, 4:90-96]

Cited: 1 time

View full text PDF listing >>



Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome.

Dev Nathani, Michael H Barnett, Judith Spies, John Pollard, Min-Xia Wang, Matthew C Kiernan,

INTRODUCTION:To improve diagnostic accuracy, in this study we compared prebiopsy clinical parameters with subsequent pathological confirmation of peripheral nerve vasculitis. METHODS:Clinical, laboratory, and neurophysiological parameters were analyzed for consecutive patients referred for nerve biopsy with suspected vasculitis. Patients were assigned pathological categories of definite, probable, possible, or absent vasculitis using ... Read more >>

Muscle Nerve (Muscle & nerve)
[2019, 59(6):643-649]

Cited: 0 times

View full text PDF listing >>



Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes).

James D Triplett, Katherine A Buzzard, Michal Lubomski, D Sean Riminton, Michael H Barnett, Miriam S Welgampola, G Michael Halmagyi, MaiAnh Nguyen, Klara Landau, Andrew G Lee, Gordon T Plant, Clare L Fraser, Stephen W Reddel, Todd A Hardy,

The triad of central nervous system symptoms, visual disturbance and hearing impairment is an oft-encountered clinical scenario. A number of immune-mediated diseases should be considered among the differential diagnoses including: Susac syndrome, Cogan syndrome or Vogt-Koyanagi-Harada disease; demyelinating conditions such as multiple sclerosis or neuromyelitis optica spectrum disorder; systemic diseases ... Read more >>

J. Neurol. Neurosurg. Psychiatry (Journal of neurology, neurosurgery, and psychiatry)
[2019, 90(8):882-894]

Cited: 0 times

View full text PDF listing >>



Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.

Yuyi You, Ling Zhu, Ting Zhang, Ting Shen, Ariadna Fontes, Con Yiannikas, John Parratt, Joshua Barton, Angela Schulz, Vivek Gupta, Michael H Barnett, Clare L Fraser, Mark Gillies, Stuart L Graham, Alexander Klistorner,

PURPOSE:To compare functional and structural changes in the retina in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). DESIGN:Cross-sectional study; biochemical study of human retinas. PARTICIPANTS:A total of 181 participants, including 22 consecutive patients (44 eyes) with NMOSD, 131 patients (262 eyes) with ... Read more >>

Ophthalmology (Ophthalmology)
[2019, 126(6):801-810]

Cited: 1 time

View full text PDF listing >>



Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.

John J Moore, Jennifer C Massey, Carole D Ford, Melissa L Khoo, John J Zaunders, Kevin Hendrawan, Yael Barnett, Michael H Barnett, Kain A Kyle, Robert Zivadinov, Kris C Ma, Sam T Milliken, Ian J Sutton, David D F Ma,

BACKGROUND:Autologous haematopoietic stem cell transplantation (AHSCT) has been explored as a therapeutic intervention in multiple sclerosis (MS) over the last two decades; however, prospective clinical trials of the most common myeloablative conditioning regimen, BEAM, are limited. Furthermore, patient selection, optimal chemotherapeutic regimen and immunological changes associated with disease response require ... Read more >>

J. Neurol. Neurosurg. Psychiatry (Journal of neurology, neurosurgery, and psychiatry)
[2019, 90(5):514-521]

Cited: 0 times

View full text PDF listing >>



Pathophysiological basis of low contrast visual acuity loss in multiple sclerosis.

James D Triplett, Con Yiannikas, Michael H Barnett, John Parratt, Joshua Barton, Stuart L Graham, Yuyi You, Alexander Klistorner,

Objective:There is currently an urgent need for reliable clinical biomarkers of remyelination to be used in Phase 2 and Phase 3 clinical trials. Low contrast visual acuity (LCVA) has been suggested as a functional measure of the integrity of the visual pathway. Therefore, the aim of this study was to ... Read more >>

Ann Clin Transl Neurol (Annals of clinical and translational neurology)
[2018, 5(12):1505-1512]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.4084 s